Mr Thoelke provides scientific and strategic oversight of product development and directs the following PRA divisions: Medical Affairs, Scientific Affairs, Global Feasibility, Medical Informatics, Patient Access and Retention Services, Investigator Networks, Orphan and Rare Diseases, and the infectious diseases and vaccines group. He has more than 21 years of experience in the global drug development, diagnostic, and device industry, offering specialized expertise in global hematology/oncology studies. Having visited over 40 countries, he is familiar with the global drug development environment and has established relationships with therapeutic experts in numerous indications around the world. Mr Thoelke has spoken widely about the current landscape of clinical trial recruitment and drug development timelines. He actively pursues novel technologies and strategies to move the current clinical drug development paradigm toward a more evidence-based strategy. A leader in the field of medical informatics, Mr Thoelke focuses on leveraging data to maximize patient enrollment by selecting high-performing sites to minimize overall drug development timelines. He is a named inventor on numerous patents in high-dose radiotherapy for the treatment of hematologic malignancies that ultimately developed into a therapeutic product.